Last reviewed · How we verify

NCT01948648

Effects of Fish Oil and Colesevelam (STAIR7007)

Status unknown NA Last updated 10 November 2020
What this trial tests

NA trial testing Colesevelam in Sitosterolemia in 13 participants. Status unknown.

Timeline
6 February 2018
Primary endpoint
30 April 2021
30 July 2021

Quick facts

Lead sponsorUniversity of Manitoba
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposebasic science
Enrollment13
Start date6 February 2018
Primary completion30 April 2021
Estimated completion30 July 2021
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of Manitoba

Who can join

8 and older, any sex, with Sitosterolemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

If treatment of colesevelam, fish oil in conjunction with ezetimibe, will lead to further reduction in plasma plant sterol levels in sitosterolemia patients. We hypothesize that treatments with fish oil, colesevelam and ezetimibe will maximize decrease in plasma concentrations of sitosterol and other plant sterols in sitosterolemia patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Colesevelam

Trials testing the same drug.

Other University of Manitoba trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01948648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing